1. Home
  2. PESI vs SKYE Comparison

PESI vs SKYE Comparison

Compare PESI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perma-Fix Environmental Services Inc.

PESI

Perma-Fix Environmental Services Inc.

N/A

Current Price

$17.89

Market Cap

367.9M

Sector

Industrials

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.57

Market Cap

9.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PESI
SKYE
Founded
1990
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
367.9M
9.0M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
PESI
SKYE
Price
$17.89
$1.57
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
252.7K
248.7K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
43.61
N/A
EPS
N/A
N/A
Revenue
$642,000.00
N/A
Revenue This Year
$34.62
N/A
Revenue Next Year
$77.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.14
$0.26
52 Week High
$21.32
$4.99

Technical Indicators

Market Signals
Indicator
PESI
SKYE
Relative Strength Index (RSI) 52.51 63.96
Support Level $14.18 $0.66
Resistance Level $19.02 $2.28
Average True Range (ATR) 0.75 0.18
MACD -0.10 -0.00
Stochastic Oscillator 27.57 58.20

Price Performance

Historical Comparison
PESI
SKYE

About PESI Perma-Fix Environmental Services Inc.

Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: